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ABSTRACT
Objective: In this study, we have made an attempt to the developed formulation of nanoparticles (NPs) of telmisartan (TLM) incorporated in 
carboxymethyl chitosan (CMCS) for the better drug delivery and enhanced bioavailability.
Materials and Methods: The NPs size and morphology were investigated by high-resolution transmission electron microscopy and field emission 
scanning electron microscopy, respectively. The crystal structures and surface functional groups were analyzed using X-ray diffraction pattern, and 
Fourier transform infrared spectroscopy, respectively.
Results: To increase the solubility of TLM by targeted delivery of the drug through polymeric NPs is an alternative efficient, option for increasing the 
solubility. TLM nanosuspension powders were successfully formulated for dissolution and bioavailability enhancement of the drug. We focused on 
evaluating the influence of particle size and crystalline state on the in vitro and in vivo performance of TLM.
Conclusion: In summary, we have developed a new approach toward the delivery of poorly water-soluble drug TLM by CMCS NPs. The particles 
having a good drug loading content and drug encapsulation efficiency. The cytotoxicity of the synthesized NPs is also very less.
Keywords: Telmisartan, Nanoparticle, Carboxymethyl chitosan, Transmission electron microscopy, Scanning electron microscopy.
INTRODUCTION
The administration of drug telmisartan (TLM) by the oral route is 
desirable but difficult due to the variable pH of the gastrointestinal 
tract. The presence of enzymes such as pepsin and the highly acidic pH 
in the stomach can cause protein degradation. There is a substantial 
loss of drug activity due to pancreatic enzymes secreted by the lumen 
of the intestine and also by membrane-bound brush-border enzymes. 
Finally, the physical barrier of the intestinal cells must be crossed 
before a drug can reach the circulation. To reduce all the above 
problems, nanoparticles (NPs), a new drug delivery system has been 
developed [1-3]. For medical purposes NPs are an attractive material 
which depends on their important and unique properties, such as 
their surface to mass ratio is much larger than that of other particles, 
their quantum properties and their ability to absorb and carry other 
compounds [4-6]. NPs of polymer not only protect the bioactive 
substance but also facilitate the control release of the material in 
delivering system [7-10]. In comparison to other polymer, chitosan 
is used extensively in drug delivery applications [11-16]. Chitosan 
can be produced in a different form such as fiber, film, paste, powder 
due to its reactive nature [17,18]. The solubility of chitosan depends 
on the free distribution of amino and N-acetyl group [19]. Chitosan 
slowly metabolizes into less harmful metabolite (amino sugars) 
which are completely absorbed by human body [20]. Carboxymethyl 
chitosan (CMCS) can be obtained by direct alkylation of chitosan. The 
CMCS achieved can be in various types: N, O-CMCS and N,N-CMCS, 
N-CMCS, O-CMCS. Different degree of substitution and different 
reaction conditions will result in the N versus O selectivity. CMCS 
is soluble in water at neutral pH. It possesses large hydrodynamic 
volume, high viscosity, film and gel forming capabilities and the other 
useful properties, such as biodegradation, biological activity, and low 
toxicity, biocompatibility all the above properties makes it an attractive 
option in relation with its use in drug delivery, food, and cosmetics. To 
synthesize O-CMCS NP we have used CaCl2 as crosslinking agent. To 
achieve targeting property, CaCl2 is incorporated into the amphiphillic 
polymers through coupling reaction between the -COOH group of CMCS 
through 2, 2’-(ethylenedioxy)-bis-(ethylamine) to obtain the final 
product. At neutral pH is expected to constitute a hydrophobic core of 
self-assembled NPs which can serve as a depot for hydrophobic drugs. 
At acidic pH, the free amines group of chitosan is to be protonated, 
causing disassembles of the NPs and eventual release of drugs [21-23].
Chitosan, a copolymer of N-acetyl-D-glucosamine and glucosamine 
linked by glycosidic bonds, is the second plentiful biomass produced 
by deacetylation of chitin. It can absorb toxic metals such as 
mercury, cadmium, and lead. It also has following properties such as 
antimicrobial, immuno-stimulation, coagulation ability, good adhesion, 
bio-degradability, biocompatibility, hemostatic, and fungistatic. In view 
of the above properties, chitosan has been used as a biomaterial for 
drug delivery, gene delivery, and other biomedical application [24-28]. 
For the preparation of mucoadhesive formulation, chitosan has been 
used [29-32]. It improves the rate of dissolution of poorly soluble 
drug for the targeted drug delivery and enhances the absorption of 
the peptide. Cell adhesion and potential cell uptake of NPs of chitosan 
should be efficient due to its positive charge which is attracted by 
negatively charged cell membranes. Since it is poorly soluble in water 
and inorganic solvents which limit its wide applications. Chitosan has 
positive charges (-NH3+) thus at relatively low pH (<6.0) are soluble in 
dilute aqueous solutions, but as the pH increases they lose their charge 
and precipitate from the solution due to de-protonation of the amino 
group [33-37].
For the prevention and treatment of hypertension TLM an, angiotensin 
II receptor antagonist is used. TLM is less soluble and highly permeable 
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because it belongs to Class II drug. The low solubility of the drug 
in biological fluids which results into poor bioavailability after oral 
administration is one of the big problems [38-41]. The solubility of 
TLM in water is very low, i.e., 0.078 mg/ml in water. Poor bioavailability 
after oral administration of the TLM is due to its bioavailability that 
is 42-58%, and biological half-life is only 24 hrs. Thus, increasing 
dissolution and aqueous solubility of TLM is of therapeutic importance 
[42-49]. Various approaches for enhancing solubility and oral efficacy 
of TLM used were solid dispersion and inclusion complexation [50-52]. 
None of the above approaches offered an adequate improvement in 
therapeutic potential due to the dosage form limitations itself. Thus, we 
used the CMCS polymers to load TLM, which have not been used to best 
of our knowledge and there is no report about the use of this based drug 
delivery. In light of these, the aim of the present investigation was done 
to design and develop novel nanoparticulate solid oral dosage forms of 
TLM by incorporating it into the CMCS.
In this research, the solubility and bioavailability of TLM in conjugation 
with various carriers using various methods were studied. Besides 
this solubility and dissolution study, the various evaluation methods 
were carried out to determine the physicochemical properties of 
solid dispersions and physical mixture in comparison to pure drug. 
To increase the solubility and for targeted drug delivery of TLM use 
of polymeric NPs is an alternative efficient, option. In this study, TLM 
nanosuspension powders were successfully formulated for dissolution 
and bioavailability enhancement of the drug. We focused on evaluating 
the influence of crystalline state and particle size on the in vitro and 




Purchases were as follows: Chitoson, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), TLM, and monochloroacetic 
acid were purchased from Sigma-Aldrich (USA). Calcium chloride, 
isopropanol were obtained from Merck India. Drug solutions were 
freshly prepared in millipore water. Organic solvents such as methanol 
and ethanol were purchased from Qualigens Fine Chemicals (Mumbai). 
Dimethyl sulfoxide (DMSO) and N,N’-dimethyl formamide were obtained 
from Merck India. Fetal bovine serum and minimum essential medium 
were procured from Hyclone (USA) and Himedia (India), respectively. 
All chemicals were used without further purification.
Methods
General procedure for preparation of CMCS
CMCS were synthesized using chitosan (1.0 g) was swelled in 50% 
(w/v) sodium hydroxide solution (40 ml) at 0°C for overnight. Further 
chitosan was washed with isopropanol and dissolve in isopropanol 
(30 ml). A reaction mixture of monochloracetic acid (3.0 g) and 
isopropanol (5 ml) was added dropwise into the chitosan mixture and 
reacted for 12 hrs at 40°C. The reaction was stopped by adding 70% 
ethyl alcohol (25 ml). The solid was filtered and washed with ethyl 
alcohol and vacuum dried at room temperature. The resulted product 
was sodium salt of CMCS [53].
Preparation of CMCS NPs
CMCS NPs were synthesized by ionotropic gelation of CMCS solution 
with calcium chloride solution. About 0.5% CMCS solution was 
prepared in distilled water. The solution (5 ml) was added in 1.5 % 
CaCl2 (1 ml) solution under continuous stirring. The resulting NPs were 
purified by centrifugation for 10 min at 15,000 rpm and lyophilized. 
A diagrammatical representation is given in Fig. 1 for better insight into 
the development of nanoparticles (NPs).
Drug loading into NPs
TLM (1 mg/mL) in the poorly water soluble drug was dissolved 
in glacial acetic acid solution (10 ml). CMCS NPs (10 mg) were 
introduced into the previously prepared drug solutions. The solution 
was shaken in an orbital shaker for 24 hrs. The suspension was then 
centrifuged at 15,000 rpm for 20 minutes to separate the NPs from 
the solutions. The procedure was repeated 3 times to eliminate any 
unloaded TLM from the suspension. The amount of loaded TLM was 
measured spectrophotometrically at 295 nm with a ultraviolet (UV)-
1700 spectrophotometer (Shimadzu). The drug loading content and 
entrapment efficiency were calculated according to the following 
equations.
( ) = ×Weight of drug in nanoparticlesDrug loading contents % 100
Weight of nanoparticles taken
( ) = ×Weight of drug in nanoparticlesDrug entrapment efficiency % 100
Weight of nanoparticles taken
Characterization of CMCS nonoparticles
Particle size and zeta potential measurement
Mean particle size its distribution were determined using dynamic 
light scattering (DLS) technique. Zeta potential was evaluated by 
measuring electrophoretic mobility of the particle using a laser-based 
multiple angle electrophoresis analyzer. TLM NPs were sufficiently 
diluted with deionized water to reduce the count rate up to 100-250 
kcps and analyzed by employing Malvern Zetasizer (Nano ZS, Malvern 
Instruments, UK). Observations were recorded in triplicate for each 
sample at 25±1°C.
Particle size measurement by transmission electron microscopy 
(TEM) and scanning electron microscopy (SEM)
Particle’s morphological characterization of TLM NPs was executed by 
SEM and TEM. Samples for SEM studies were prepared by clinging the 
NPs on a double adhesive tape stuck to an aluminium stub and were 
coated with gold and palladium under an argon atmosphere utilizing 
a high-vacuum eveporator (Polaron SEM coating system). Samples 
were scanned through an electron microscope (EVO-50, ZEISS; UK) and 
photomicrographs were captured. For TEM, a drop of optimized NP 
suspension in aqueous solution was placed on a carbon film coated on 
a copper grid and freeze dried. Then, NPs were observed at 80 kV using 
Tem TECNAI G2 20 S-TWIN (FEI Netherlands) instrument, from Indian 
Institute of Toxicology Research (IITR), Lucknow.
Aggregation state of TLM nanopartices
The physical and chemical aggregation state of TLM was evaluated 
using UV and Fourier transform infrared (FTIR) spectroscopy. The FTIR 
spectrums of TLM and drug loaded chitosan NPs (freeze dried) were 
obtained using spectrometer (Perkin Elmer). A total of 2 mg of sample 
was mixed with 100 mg of dry potassium bromide (KBr) and the mixture 
was ground into fine powder using a mortar before compressing into 
(KBr) disk under a hydraulic press at 10,000 psi. Each KBr disk was 
then scanned at 4 mm/s at a resolution of 2/cm over a wave number 
region of 400-4000/cm using IR solution (software ver. 1.10). The 
characteristics peaks of functional groups in the drug samples were 
determined and compared with pharmacopoeial standards, and the 
Fig. 1: Schematic representation of synthetic procedure of 
carboxymethyl chitosan-telmisartan
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possible interactions between drug and excipients were analyzed by 
obtained data. The electronic configuration of TLM NPs was elucidated 
by a UV spectrophotometer (UV 1700, Shimadzu, Japan). Lyophilized 
DTX-NCs were dispersed in triple-distilled water (3.0 mL) and scanned 
in the range from 200 to 400 nm. The UV spectrum of pure TLM was 
taken after solubilizing it in methanol.
Evaluation studies
Dissolution studies
In-vitro drug release study for optimized formulations of TLM loaded 
polymeric NPs was conducted in triplicate by equilibrium dialysis 
membrane method. The amount of drug release from the formulation 
was measured using spectroscopic method. The experiment was 
performed by taking specified volume of formulation in hermetically 
sealed dialysis membrane. The dialysis bag was suspended in pH 7.4 
phosphate buffer saline (PBS) at 37°C being stirred at 240 rpm. Samples 
were collected at predetermined time points, and subsequently, media 
was replenished with pH 7.4 PBS after each sampling to maintain sink 
conditions.
In vivo studies
The experiments were carried out using adult male animals 
spontaneously hypertensive rat (SHRs) (225-250 g, 8-9 weeks old) 
procured from the laboratory animal services division of Central drug 
research Institute, Lucknow, India. Experiments were performed 
according to internationally followed ethical standards and approved 
by the Institutional animal ethics committee. They were kept in a 
polyacrylic cage (22.5 cm × 37.5 cm) and were maintained under 
standard housing conditions (24-27°C and humidity 60-65%) with a 
12 hrs light and dark cycle. They were fed a standard chow diet and 
water were available but were withdrawn 1 hr before administration 
of drugs till completion of the trial. After the 1-week acclimatization 
period, animals were used of experiments, and all efforts were made to 
minimize animal suffering.





Measurement of blood pressure (BP) and heart rate (HR) using the 
telemetry system SHRs and maintained at 37°C on a servo controlled, 
heated rodent operating table. SHRs had a BP catheter attached to a 
telemeter inserted into their abdominal aorta. Hemodynamic data were 
measured over a 10 seconds interval every 5 minutes.
Dose 1 was used for vehicle-treated control. BP (mmHg) and HR 
(beats/min) were measured. Each treatment by single injection (n=6) 
was performed with an interval of several days between each injection 
for washout and return to higher systolic BP (SBP) (200 mmHg). Mean 
arterial pressure and HR were recorded continuously in telemetered 
rats and data were collected over 24 hrs after injection.
Cytotoxicity study
MTT assay
Non-cytotoxic dose of chitosan, formulation, and combination of 
chitosan + formulation was identified in HaCaT, MCF-7, A549, and 
HepG2 human cell lines. Cytotoxicity assessment was done using 
standard endpoint, i.e., tetrazolium bromide MTT assay. In brief, cells 
(1 × 104 cells/well) were seeded in 96-well tissue culture plates and 
incubated in the CO2 incubator for 24 hrs at 37°C. Then, the medium 
was aspirated and cells were exposed to medium containing either 
of chitosan, formulation, and combination of chitosan + formulation 
(0.001-100 µg/ml) for 24-96 hrs at 37°C in 5% CO2-95% atmosphere 
under high humid conditions. Tetrazolium salt (10 µl/well; 5 mg/ml of 
stock in PBS) was added 4 hrs before completion of respective incubation 
periods. At the completion of incubation period, the reaction mixture 
was carefully taken out and 200 µl of culture grade DMSO was added 
to each well. The content was mixed well by pipetting up and down 
several times until dissolved completely. Plates were then incubated for 
10 minutes at room temperature and color was read at 550 nm using 
multiwell microplate reader (Synergy HT, Bio-Tek, USA). The unexposed 
sets were also run parallel under identical conditions that served as a 
basal control.
Neutral red uptake (NRU) assay
The assay was carried out following the protocol described earlier 
by Siddiqui et al. [54]. Cells were exposed to compound in identical 
experimental setup as to MTT assay. On the completion of incubation 
period, medium was aspirated and NRU salt (50 µM/mL in medium) 
was added 100 µl per well plate and incubated for 3 hrs. Then, the 
reaction mixture was carefully taken out and plates were washed with 
washing solution (100 µl/well) containing 1% CaCl2 (w/v) and 0.5% 
Formaldehyde for HCHO (v/v) to remove unincorporated dye. Washing 
solution was removed and mixture of 200 µl; 1% acetic acid and 50% 
ethanol was added. The plates were kept on rocker shaker for 10 min 
at room temperature and then analyzed at 540 nm using multi-well 
microplate reader (Synergy HT, Bio-Tek, USA). Unexposed sets were 
also run under identical condition and served as control.
Lactate dehydrogenase (LDH) release assay
LDH release assay is a method to measure the membrane integrity as a 
function of the amount of cytoplasmic LDH released into the medium. 
The assay was carried out using readymade commercially available LDH 
assay kit for in vitro cytotoxicity evaluation (TOX-7, Sigma St. Louis, MO., 
USA). The assay was based on the reduction of nicotinamide adenine 
dinucleotide (NAD) by the action of LDH. The resulting reduced NAD 
(NADH+) was utilized in the stochiometric conversion of a tetrazolium 
dye. The resulting colored compound was measured using multiwell 
plate reader at wavelengths 490 and 690 nm. In brief, the cells were 
exposed with (0.001-100 µg/ml) for different time periods after the 
completion of respective time periods the cells were processed for 
LDH release assay similar to MTT assay. Culture plates were removed 
from CO2 incubator as per the experimental schedule and centrifuged 
at 250 × g for 4 minutes. Then, supernatant of each well was transferred 
to a fresh flat bottom 96 well culture plate and processed further for 




FTIR study was conducted to characterize any possible interaction 
between drug and CMCS NPs. The characteristic peaks at 3420/cm (O–H 
stretching and N–H stretching vibrations), 1583/cm (corresponding 
to the amino groups), 1645, 1548/cm (amide I and amide II of amino 
group), and 1076/cm (C–O–C stretching vibration) confirms the 
formation of CMCS, as shown in Fig. 2.
DLS
The hydrodynamic diameter of CMCS NPs are measured by DLS is 
150±10 nm, whereas that of TLM loaded NPs is 160±10 nm as shown 
in Fig. 3. Results representing that there is no big change between the 
two types of NPs, which demonstrates that the size distribution are not 
significantly affected during the encapsulation of TLM. In physiological 
conditions, the NPs are very stable and the stability was maintained 
for 12 days. In the stability study, on aggregation or precipitation of 
NPs was observed during the course of storage. Moreover, changes in 
particle size of the NPs of the study were very negligible. Zeta potential 
(ζ)	 is	 an	 electric	potential	 of	 the	 shear	plane	 attached	 to	 the	moving	
particles in the medium and it is generally utilized for the prediction of 
stability of nanosuspensions. The decrease in zeta potential value with 
decrease in concentration of stabilizer may be attributed to the inability 
of stabilizer to prevent particle agglomeration at lower concentrations. 
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The reults of the optimized batches of TLM loaded nanosuspension 
depicted the zeta potential values of more than 30 mV, which suggested 
physical stable formulation developed [9].
TEM
The characterization of morphology and size of the nanopaticles are 
performed using the TEM technique. TEM micrographs were obtained 
with an acceleration voltage of 200 kV. A drop of sample solution was 
placed onto a copper grid with carbon, taped with a filter paper to 
remove surface solvent, and air-dried for 2 minutes. The study results 
are shown in Fig. 4.
SEM
SEM was used to determine the particle size and surface morphology of 
the NPs. The study reveals that the surface of the NPs was smooth and 
Fig. 2: Fourier transform infrared spectra of carboxymethyl 
chitosan (CMCS), CaCl2, telmisartan (TLM) and CMCS-TLM
Fig. 3: Hydrodynamic diameter of telmisartan loaded 
nanoparticles measured by dynamic light scattering
Fig. 6: In-vitro release studies of telmisartan nanoparticles
Fig. 7: The effect of telmisartan treatment on blood pressure in 
spontaneously hypertensive rats
Fig. 4: (a-d) Transmission electron microscopy photograph of 
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no aggregate were found from the sample used for SEM analysis. The 
particle size of the NPs was found to be 100 nm. The study results are 
shown in Fig. 5.
Evaluation studies
In-vitro drug release studies
The In-vitro release studies were carried out using dialysis membrane. 
The cumulative percentage drug release after 48 hrs was found to 
be. The significantly lower values of TLM loaded nanosuspension 
suggested market improvement in dissolution rate of by the developed 
nanosized formulation in dissolution velocity of TLM NPs could be 
attributed to the reduction in particle size, in surface area, and decrease 
in diffusion distance, whereas the incomplete drug release of drug 
particles could be attributed to the large crystal size Fig. 6.
In vivo studies
To determine the effect of TLM treatment on BP in SHR rats, we 
measured the SBP of the group rats every week. The baseline SBP 
in SHRs was 170±2 mm Hg which was much higher than in WKY 
(121±1 mmHg, p<0.001). Administration of nano TLM in the dose of 
5 mg/kg concentration showed a significant decrease in SBP than the 
administration of 5 mg/kg TLM showed a substantial decrease in SBP 
at the end of week, showed significant reduction when compared with 
the vehicle control SHR rats Fig. 7.
Cytotoxicity study
MTT assay
The highlights of the data of cytotoxicity activity of test compounds 
on independent exposure as well as in combination are summarized 
in Figs. 8-10. A time and dose-dependent decrease in percent cell 
viability was observed in all the cells used in the study. However, none 
of the concentration could induce loss of all viability upto statistically 
significant level in any cell type. HaCat, a normal human cell line 
was used as positive control against the human cancer cell lines of 
different origin viz., HepG2 (hepatoma cells), A549 (lund epithelium 
carcinoma cells) and MCF-7 (human breast adenocarcinoma cells). 
However, no cell specific changes could be recorded and there was a 
non-significant loss of cell viability with more or less equal magnitude 
in all the cell types. Hence, the effect of chemicals could be speculated 
due to cytostatic responses, not due to anti-cancer activity. Although 
the combination of both the test compounds increases the magnitude 
of percent cell viability loss, could not attain the significant levels. In the 
present investigations, both the test compounds were found to be non-
cytotoxic/non anti-carcinogenic upto 100 µg/ml concentration for a long 
term exposure, i.e., till 96 hrs in human cancer cells of different origin. 
Even the combination of these two test compounds were also not able 
to brought the effect to the significant level. In cytotoxic investigations, 
both the test compounds (CMCS, CMCS-TLM NP) were found to be non-
cytotoxic/non-anti-carcinogenic upto 100 µg/ml concentration for a 
long term exposure, i.e., till 96 hrs in human cancer cells of different 
origin. Even, the combination of these two test compounds were also 
not able to brought the effect to the significant level.
CONCLUSION
In summary, we have developed a new approach toward the delivery 
of poorly water soluble drug TLM by CMCS NPs. The particles having 
a good drug loading content and drug encapsulation efficiency. The 
cytotoxicity of the synthesized NPs are also very less.
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